Literature DB >> 10805189

Headaches in patients with neurofibromatosis-1.

F J DiMario1, S Langshur.   

Abstract

An analysis of patients followed with a diagnosis of neurofibromatosis-1 and headache was conducted. Characterization of headache type was done after chart review of 81 patients with neurofibromatosis-1 and headache. Consent was obtained for subsequent telephone interviews using a standardized questionnaire concerning the onset, characteristics, timing, triggers, and associated symptoms of the patients' headaches. Data was summarized and tabulated. Of 132 patients with neurofibromatosis-1, 81 were identified with any headache by screening history. Recurrent headaches were present in 77% of patients and in 47% of our neurofibromatosis-1 clinic population. Fifty-three of 81 patients were accessible for and agreeable to telephone interview. There were 23 male patients and 30 female patients aged 5 6/12 to 49 6/12 years, with a mean age of 20.9 years. Eighty-one percent reported having experienced recurrent headaches within the year. The majority reported onset of headache prior to the age of 10 years. Headache characteristics included the following: frequency of monthly or less, frontotemporal location, pulsating or pressing quality, and moderate severity (pain scale 4 to 5 out of 10). Headaches interfered with daily activities, had weekend occurrence, and had a duration less than 2 hours. Common headache triggers included stress, "change in weather," menstruation, fatigue, and certain foods. A high percentage of patients reported associated symptoms of nausea with or without vomiting (37%), phonophobia, photophobia, pallor, and visual scotoma. We classified 34% of the patients as having migraine (25% with aura, 9% without aura), 45% with nonmigrainous headache only, and 15% with mixed headache types (either intermittently), and 7.5% with other head pains. We conclude that patients with neurofibromatosis-1 are at greater risk for headaches than the general population. While the prevalence of both migraine and nonnigraine headache is somewhat greater than in the general population, the proportion of tension-type headache, especially in young children, is greater than expected.

Entities:  

Mesh:

Year:  2000        PMID: 10805189     DOI: 10.1177/088307380001500406

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  16 in total

1.  Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life.

Authors:  Pamela L Wolters; Katherine M Burns; Staci Martin; Andrea Baldwin; Eva Dombi; Mary Anne Toledo-Tamula; William N Dudley; Andrea Gillespie; Brigitte C Widemann
Journal:  Am J Med Genet A       Date:  2015-05-14       Impact factor: 2.802

2.  Occipital peripheral nerve stimulation in the management of chronic intractable occipital neuralgia in a patient with neurofibromatosis type 1: a case report.

Authors:  Ioannis Skaribas; Octavio Calvillo; Evangelia Delikanaki-Skaribas
Journal:  J Med Case Rep       Date:  2011-05-10

3.  Cerebral arteriopathy in neurofibromatosis type 1.

Authors:  Rk Sanjeev; S Kumaravelu
Journal:  Med J Armed Forces India       Date:  2012-01-18

4.  Substantial pain burden in frequency, intensity, interference and chronicity among children and adults with neurofibromatosis Type 1.

Authors:  Alanna M Kongkriangkai; Christopher King; Lisa J Martin; Emily Wakefield; Carlos E Prada; Geraldine Kelly-Mancuso; Elizabeth K Schorry
Journal:  Am J Med Genet A       Date:  2019-02-08       Impact factor: 2.802

5.  Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models.

Authors:  David K Meyerholz; Georgina K Ofori-Amanfo; Mariah R Leidinger; J Adam Goeken; Rajesh Khanna; Jessica C Sieren; Benjamin W Darbro; Dawn E Quelle; Jill M Weimer
Journal:  J Histochem Cytochem       Date:  2017-08-28       Impact factor: 2.479

6.  Pain, skin sensations symptoms, and cognitive functioning predictors of health-related quality of life in pediatric patients with Neurofibromatosis Type 1.

Authors:  James W Varni; Kavitha Nutakki; Nancy L Swigonski
Journal:  Qual Life Res       Date:  2018-11-21       Impact factor: 4.147

7.  Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report.

Authors:  Staci Martin; Shawn Nelson Schmitt; Pamela L Wolters; Brittany Abel; Mary Anne Toledo-Tamula; Andrea Baldwin; Rikard K Wicksell; Melinda Merchant; Brigitte Widemann
Journal:  Pain Med       Date:  2014-11-06       Impact factor: 3.750

Review 8.  Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.

Authors:  Shreya S Bellampalli; Rajesh Khanna
Journal:  Pain       Date:  2019-05       Impact factor: 6.961

9.  Nutraceuticals safety and efficacy in migraine without aura in a population of children affected by neurofibromatosis type I.

Authors:  Marco Carotenuto; Maria Esposito
Journal:  Neurol Sci       Date:  2013-03-27       Impact factor: 3.307

10.  The evaluation and management of paediatric headaches.

Authors:  Jm Dooley
Journal:  Paediatr Child Health       Date:  2009-01       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.